Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prospects for better tuberculosis vaccines.

H L Collins1, S H Kaufmann

  • 1Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany. collins@mpiib-berlin.mpg.de

The Lancet. Infectious Diseases
|March 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic gene transfer of binding immunoglobulin protein (BiP) prevents disease progression in murine collagen-induced arthritis.

Clinical and experimental immunology·2014
Same author

Monitoring of diamondback moth (Lepidoptera: Plutellidae) resistance to spinosad, indoxacarb, and emamectin benzoate.

Journal of economic entomology·2006
Same author

Increased susceptibility to ventricular arrhythmias in hypertensive paraplegic rats.

Clinical and experimental hypertension (New York, N.Y. : 1993)·2003
Same author

Monitoring and characterization of diamondback moth (Lepidoptera: Plutellidae) resistance to spinosad.

Journal of economic entomology·2002
Same author

Daily exercise reduces measures of heart rate and blood pressure variability in hypertensive rats.

Clinical and experimental hypertension (New York, N.Y. : 1993)·2002
Same author

Different cross-resistance patterns in the diamondback moth (Lepidoptera: Plutellidae) resistant to Bacillus thuringiensis toxin Cry1C.

Journal of economic entomology·2002
Same journal

Cefiderocol heteroresistance in NDM Enterobacterales.

The Lancet. Infectious diseases·2026
Same journal

Correction to Lancet Infect Dis 2020; 20: 37-59.

The Lancet. Infectious diseases·2026
Same journal

Correction to Lancet Infect Dis 2020; 20: 60-79.

The Lancet. Infectious diseases·2026
Same journal

Expert consensus on case definitions in human loiasis: a Delphi study.

The Lancet. Infectious diseases·2026
Same journal

The Bundibugyo virus disease outbreak: a warning signal for risks to health workers.

The Lancet. Infectious diseases·2026
Same journal

Trials of medical countermeasures to begin in DR Congo.

The Lancet. Infectious diseases·2026
See all related articles

Tuberculosis is a major infectious killer, and current vaccines are failing. This review covers new tuberculosis vaccine research, focusing on candidate antigens and evaluation methods for a more effective vaccine.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Vaccinology

Background:

  • Tuberculosis (TB) is a leading cause of infectious disease mortality globally.
  • Current TB treatments are lengthy, costly, and challenged by rising drug-resistant Mycobacterium tuberculosis strains.
  • The existing Bacillus Calmette-Guérin (BCG) vaccine exhibits variable efficacy, particularly in high-incidence regions.

Purpose of the Study:

  • To review the current landscape of novel tuberculosis vaccine research.
  • To highlight promising candidate antigens for next-generation TB vaccines.
  • To discuss methodologies employed in evaluating new TB vaccine candidates.

Main Methods:

  • Literature review of recent studies on tuberculosis vaccine development.
  • Analysis of identified candidate antigens and their immunological targets.

Related Experiment Videos

  • Examination of preclinical and clinical evaluation strategies for vaccine efficacy.

    • Main Results:

    • Several novel vaccine strategies and candidate antigens are under investigation.
    • Emerging research focuses on subunit vaccines, viral vectors, and novel delivery systems.
    • Standardized evaluation methods are crucial for assessing vaccine immunogenicity and protective efficacy.

    Conclusions:

    • Development of a more effective tuberculosis vaccine is urgently needed.
    • Continued research into diverse antigens and robust evaluation platforms is essential.
    • Advancements in vaccinology offer hope for improved control of tuberculosis.